- Home
- HE vs MRVI Comparison
HE vs MRVI Comparison
Compare HE & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | MRVI |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 559.0M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HE | MRVI |
|---|---|---|
| Price | $13.63 | $5.04 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.25 | $4.13 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.32 | 14.29 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $3,086,896,000.00 | $185,743,000.00 |
| Revenue This Year | $7.00 | $12.54 |
| Revenue Next Year | $4.06 | $7.87 |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.20 | $1.99 |
| 52 Week High | $17.33 | $5.21 |
Technical Indicators
Market Signals| Indicator | HE | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 70.68 |
| Support Level | $13.11 | $3.27 |
| Resistance Level | $13.93 | N/A |
| Average True Range (ATR) | 0.32 | 0.24 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 65.90 | 83.88 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.